¡Ya estamos en !
Descubre más
CDAK
Codiak BioSciences
Dejó de cotizar
CDAK dejó de cotizar en bolsa el 4 de abril de 2023.
Acerca de: Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Empleados: 53
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
No hemos recibido artículos de noticias recientes sobre CDAK.
Gráficos de precios implementados con Lightweight Charts™